Trevena
TRVN
$0.39
Share price
-4.40%
Change (1 day)
-39.85%
Change (1 year)
Categories
Trevena (TRVN) - Total debt
Total debt on the balance sheet as of September 2023 : $35.31 M
According to Trevena's latest financial reports the company's total debt is $35.31 M. A company’s total debt is the sum of all current and non-current debts.
Trevena - Total debt on balance sheet (from 2012 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $19.76 M | 178.34% |
| 2021-12-31 | $7.1 M | -9.01% |
| 2020-12-31 | $7.8 M | -42.03% |
| 2019-12-31 | $13.46 M | -22.65% |
| 2018-12-31 | $17.4 M | -38.25% |
| 2017-12-31 | $28.18 M | 53.77% |
| 2016-12-31 | $18.32 M | 0.73% |
| 2015-12-31 | $18.19 M | 968% |
| 2014-12-31 | $1.7 M | |
| 2013-12-31 | $N/A | -100% |
| 2012-12-31 | $4.86 M | 995.14% |
| 2011-12-31 | $0.44 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | $64.61 B | 182,872.28% | 🇺🇸 USA |
 Merck MRK | $35.05 B | 99,169.39% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Cytokinetics
CYTK | $0.75 B | 2,040.21% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | $3.36 M | -90.46% | 🇺🇸 USA |
 Cara Therapeutics
CARA | $6.08 M | -82.76% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |